Jared Kaltwasser

Patients in the highest risk category had a 65% chance of recurrence of their perihilar cholangiocarcinoma (PHCC) within 1 year, this new study has found.

Only about 11% of patients received care meeting a composite quality metric, a study found.

The patient was successfully treated with rituximab and intravenous immunoglobulin.

However, patient-reported scores were not significantly better in the tocilizumab group.

A new study looks at the balancing act physicians and families must carry out when managing expectations at a time of great scientific advancement in spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD).

At 12 weeks, nearly 8 in 10 patients had significant improvement.

The case involved a 69-year-old man who presented with lupus nephritis.

A new review article explains the role of biologics in treatment systemic lupus erythematosus (SLE) and lupus nephritis.

New data show litifilimab outperformed placebo in patients with active arthritis and skin manifestations due to systemic lupus erythematosus (SLE).

About 4 in 10 patients do not receive curative therapy despite early detection, a new study shows.

A study carried out at 4 health care systems found rates of stage I lung cancer increased, and rates of stage IV cancer decreased, once screening was initiated.

Chimeric antigen receptor (CAR) T-cell therapies may help patients with otherwise refractory cases of multiple myeloma, but patients must overcome significant hurdles to access the therapy.

This study suggests that the diaphragm may fare differently from other muscles in spinal muscular atrophy (SMA).

The authors found the association by comparing echocardiographic and biochemical changes after 5 years in patients with systemic lupus erythematosus (SLE).

The findings suggest that sequential mutant IDH inhibitor therapy might be one way to fight resistance in metastatic intrahepatic cholangiocarcinoma (IHCC).

A new therapeutic paradigm has heightened the need for meaningful measures of assessing patients.

A new study finds anxiety and depression are more common in people with systemic lupus erythematosus (SLE) if they also have nephritis.

The increase in the incidence of hepatocellular carcinoma in Louisiana was nearly double that of the United States as a whole between 2005 and 2015.

A new analysis found only 1 in 10 studies of inequities in liver cancer had a European focus or origin.

The findings mean it may be feasible to use adult systemic lupus nephritis (SLE) trial data to reduce the data needed for pediatric indications.

About 1 in 7 people with systematic onset juvenile idiopathic arthritis (SJIA) will not respond to interleukin-1 or interleukin-6 inhibitors.

New research suggests Nestin expression can help distinguish combined hepatocellular-cholangiocarcinomas (CCAs) from hepatocellular carcinomas and intrahepatic cholangiocarcinomas.

The use of existing guidelines for pediatric treatment varies significantly among sites, a new study has found.

A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.

A new review outlines what is known about cardiovascular disease (CVD) risk in patients with systemic lupus erythematosus (SLE) and how that might affect patient care.

The procedure can be beneficial prior to chemotherapy, but it also has high rates of complications, this new analysis shows.

Most participants were able to complete the assessments at home, and their scores correlated well with in-clinic assessments.

A new case report highlights the potential benefits of risk assessment for women with a family history of autoimmune diseases, such as systemic lupus erythematosus (SLE), who are considering the human papillomavirus (HPV) vaccine.

The new report reverses previous research suggesting that White men who consumed large amounts of gamey meat and rich foods were most at risk.

A new report offers insights from a multidisciplinary team of experts on intrahepatic cholangiocarcinoma (iCCA).